Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC318 Alone or With Pembrolizumab in Advanced NSCLC
NCT04699123Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Feb 2021
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nc318 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Yale University. Primary endpoints: Objective Response Rate up to 4 years and Number of participants with treatment related adverse events at 6 weeks. Started Feb 2021; status: active, not recruiting.
02
Drugs
nc318
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04699123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699123.